Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF-Mutant Melanoma

CONCLUSIONS: Our study highlights the value of NGS in detecting BRAF, NRAS mutations and RAF fusions, expanding possibilities for targeted therapies in malignant melanoma. Belvarafenib showed clinical benefit in patients harboring these alterations. Ongoing trials will provide further insights into the safety and efficacy of belvarafenib.PMID:38470950 | DOI:10.1093/oncolo/oyae018

Source: The Oncologist - March 12, 2024 Category: Cancer & Oncology Authors: Kyoo Hyun Kim Sungmin Cho Yeyeong Jeong Eun Sil Baek Chung Lee Hyang-Joo Ryu Young Su Noh Yoon-Hee Hong Kee Yang Chung Mi Ryung Roh Byung Ho Oh Chang Gon Kim Minkyu Jung Sang Joon Shin Source Type: research